SPRY Jul 2024 7.500 call
| Previous Close | 1.2000 |
| Open | 0.8500 |
| Bid | 0.0000 |
| Ask | 0.0000 |
| Strike | 7.50 |
| Expire Date | 2024-07-19 |
| Day's Range | 0.8500 - 1.2000 |
| Contract Range | N/A |
| Volume | |
| Open Interest | N/A |
- GlobeNewswire
ARS Pharmaceuticals Announces EURneffy (adrenaline nasal spray) Recommended for Approval by CHMP for Emergency Treatment of Allergic Reactions (anaphylaxis)
EURneffy positioned to be the first and only needle-free adrenaline option authorized for emergency treatment of allergic reactions (anaphylaxis) in Europe Positive CHMP opinion and recommendation for approval of a mixed application for marketing authorization based on comprehensive data package comparing EURneffy to approved injectable products across a range of dosing scenarios as well as supportive historical data from injectable products Same data package under review by FDA with a PDUFA dat
Simply Wall St.US Growth Companies With High Insider Ownership To Watch
As the U.S. stock market experiences subtle gains with significant movements in tech giants like Amazon, investors are keenly watching the landscape for opportunities. In this environment, growth companies with high insider ownership may offer unique advantages, as aligned interests between management and shareholders can signal strong confidence in a company's future prospects.
Simply Wall St.Owning 30% shares,institutional owners seem interested in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY),
Key Insights Institutions' substantial holdings in ARS Pharmaceuticals implies that they have significant influence...
